Pharmacy

Your Article Summary

See Latest Articles

Absenteeism and health-benefit costs among employees with MS
Current Medical Research and Opinion, 06/25/09

Brook RA et al. - Patients treated with 'A' reported significantly lower SL costs, SL days, and STD costs than patients treated with 'C', suggestive of greater real world benefits with 'A'. Despite small sample sizes and the retrospective nature, the study provides interesting insights into the use of DMTs in MS. The study also revealed important areas of future research, specifically the need for development of methods to determine which MS patient groups respond best to which DMT treatments.

Today in Neuro/Psych pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia
Neuropsychopharmacology, 12/15/09

Treatment with Olanzapine is Associated with Modulation of the Default Mode Network in Patients with Schizophrenia
Neuropsychopharmacology, 12/15/09

An investigation of the ability of elemene to pass through the blood-brain barrier and its effect on brain carcinomas
Journal of Pharmacy and Pharmacology, 12/15/09

 See all of Neuro/Psych pharmacology

Today in Pharmacoeconomics...keeping you current

Receive free subspecialty "5-minute updates" via email

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Cost Effectiveness and Resource Allocation, 12/15/09

Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden
Current Medical Research and Opinion, 12/14/09

Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin
Current Medical Research and Opinion, 12/11/09

 See all of Pharmacoeconomics